Readout Newsletter: Compass, Nektar, Centivax, Curevo
Meghana Keshavan , 2025-06-24 14:11:00 Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we talk about the readout of Compass Pathways’ psilocybin trial for major depressive disorder, see more vaccine concern and turnover at the FDA, and report from the…